Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare Accredits Scotland s Nyrion to Offer CodeLink Array Services

GLASGOW, Scotland, July 19 (GenomeWeb News) - Nyrion, a gene knockdown and expression-analysis shop, has been accredited by GE Healthcare to offer CodeLink microarrays as part of an expression-analysis service, officials from both companies confirmed today.


Peter Estibeiro, managing director of the Edinburgh, Scotland-based start-up, said that Nyrion has been accredited to offer CodeLink as part of its service in the UKmarket, as well as to international customers.


Estibeiro spoke with GenomeWeb News at the BioScience 2005 conference, held here this week.


Penny Owen, a GE Healthcare marketing director, confirmed the deal had closed in recent weeks. An official announcement from both parties is pending, according to Estibeiro.


In addition to the CodeLink offering, Nyrion sells antisense and siRNA   reagents on its AccessArray 4000 system, as well as other reagents, according to the company's commercial literature.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.